Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10534780 | 0.82 | TSHR (0.46) | CYP3A4TSHRALDH1A1TP53TDP1 | |
| SCHEMBL28018184 | 0.81 | SMN1; SMN2 (0.38) | CYP3A4TSHRALDH1A1TP53TDP1 | |
| SCHEMBL12986536 | 0.81 | CYP3A4 (0.40) | CYP3A4TSHRALDH1A1TP53TDP1 | |
| SCHEMBL25162201 | 0.76 | CYP3A4 (0.40) | CYP3A4TSHRALDH1A1TDP1POLB | |
| SCHEMBL262306 | 0.76 | ALDH1A1 (0.56) | CYP3A4TSHRALDH1A1TP53TDP1 | |
| Ammonia Solution, Strong SCHEMBL2045015 | 0.73 | ALDH1A1 (0.53) | CYP3A4TSHRALDH1A1TP53TDP1 | |
| Hydrochloric Acid SCHEMBL8643161 | 0.73 | ALDH1A1 (0.53) | CYP3A4TSHRALDH1A1TP53TDP1 | |
| SCHEMBL10073373 | 0.72 | ALDH1A1 (0.43) | CYP3A4TSHRALDH1A1TP53TDP1 | |
| SCHEMBL11801313 | 0.72 | BCL2 (0.32) | — | |
| SCHEMBL10536002 | 0.71 | ALDH1A1 (0.40) | CYP3A4TSHRALDH1A1TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230002790-A1 | POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220154219-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | THE JOHNS HOPKINS UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | MYOC, MTREX, SLC26A4 | CYP3A4 4725/4885TSHR 905/4885ALDH1A1 2505/4885 |
| US-20220154219-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | PBK, MICA, STAT3 | CYP3A4 4838/4885TSHR 3092/4885ALDH1A1 4160/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | CYP3A4 4140/4885TSHR 3981/4885ALDH1A1 3433/4885 |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | POLRMT, HDGF, PCNP | CYP3A4 4140/4885TSHR 3981/4885ALDH1A1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.